ClinicalTrials.gg
Sign In
Status unknownNCT00375635Updated Sep 13, 2006

Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis

An interventional study of mFPSA treatment in Uremia, sponsored by Rigshospitalet, Denmark. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2006-09-13.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Sep 2006), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to examine removal of protein bound uremic substances by mFPSA in chronic hemodialysis patients. mFPSA is an extracorporal blood purification system developed for detoxification in acute liver failure by removal of protein bound as well as water soluble substances.

Read the detailed description

Measurements of uremic protein bound substances before and after mFPSA and a preceding routine hemodialysis session.

02

Conditions studied

  • Uremia

Browse trials for

Keywords

  • mFPSA
  • Uremic toxins
  • Protein bound toxins
  • Uremia
  • Chronic hemodialysis
03

In context

Uremia

53 studies on the registry are indexed under Uremia; 10 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 38 interventional studies indexed under Uremia.

Browse Uremia studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,007 studies on the registry; 175 are open to participants now.

Browse Rigshospitalet, Denmark studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over the age of 18
  • Anuria
  • Chronic hemodialysis dependence

Exclusion criteria

Exclusion Criteria:

  • No present history of bleeding episodes
  • Cardiac diseases
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants

Interventions

  • ProceduremFPSA treatment
06

What researchers measure

Primary outcomes

  1. Blood pressure

  2. Safety serological parameters

  3. Concentrations of protein bound uremic toxins

Secondary outcomes

  1. Bleeding episodes

07

Study locations

1 of 1 sites recruiting
  • Rigshospitalet
    Copenhagen, 2200, Denmark
    Recruiting
    • Mette B Damholt, MD,Ph.d. · Contactdamholt@dadlnet.dk · +45 35450589
    • Mette B Damholt, MD,Ph.d. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2006
First posted
Sep 13, 2006
Start
Mar 2006
Completion
Oct 2006
Last update
Sep 13, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Sep 13, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00375635
Lead sponsor
Rigshospitalet, Denmark
First posted
Sep 13, 2006
Start date
Mar 2006
Completion
Oct 2006
Last update
Sep 13, 2006

Study contacts

Mette B Damholt, MD,Ph.d.
Contact
damholt@dadlnet.dk
+45 35453545 ext. 50589
Soren D Ladefoged, MD
Contact
SOERENRH04736LADEFOGED@rh.dk
+45 35453545 ext. 51020
Mette B Damholt, MD,Ph.d.
principal investigator · Rigshospitalet P2132
Soren D Ladefoged, MD
principal investigator · Rigshospitalet, Denmark
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uremia →

Other studies from this sponsor

Rigshospitalet, Denmark →

Start the discussion